| Not Yet Recruiting | Masitinib in Patients With Mild Alzheimer's Disease Alzheimer Disease | Phase 3 | 2026-06-01 |
| Not Yet Recruiting | Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | 2026-01-01 |
| Unknown | Masitinib for the Treatment of Severe Mast Cell Activation Syndrome Mast Cell Activation Syndrome | Phase 2 | 2022-07-01 |
| Active Not Recruiting | Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple S Progressive Multiple Sclerosis | Phase 3 | 2022-06-28 |
| Recruiting | AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2022-06-01 |
| Unknown | Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 Covid19, SARS-CoV2 Infection, Coronavirus Disease 2019 | Phase 2 | 2021-11-23 |
| Recruiting | Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients Amyotrophic Lateral Sclerosis | Phase 3 | 2021-02-02 |
| Unknown | Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment Indolent Systemic Mastocytosis | Phase 3 | 2020-07-01 |
| Unknown | Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Sever SARS-CoV 2, COVID-19, Coronavirus Disease 2019 | Phase 2 | 2020-06-01 |
| Completed | Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male Subjects Healthy Volunteers | EARLY_Phase 1 | 2017-07-31 |
| Completed | Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels Asthma | Phase 3 | 2016-12-01 |
| Terminated | Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence Gastro-Intestinal Stromal Tumour | Phase 3 | 2015-07-01 |
| Completed | Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorec Colorectal Cancer Metastatic | Phase 2 / Phase 3 | 2015-07-01 |
| Completed | Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer Metastatic Castrate Resistant Prostate Cancer | Phase 3 | 2014-09-01 |
| Completed | Masitinib Plus Gemcitabine in Pancreatic Cancer Locally Advanced or Metastatic Pancreatic Cancer | Phase 3 | 2014-07-01 |
| Completed | Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients Ovarian Cancer | Phase 2 / Phase 3 | 2014-04-01 |
| Terminated | Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer Metastatic Colorectal Cancer | Phase 3 | 2014-01-01 |
| Completed | Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclero Amyotrophic Lateral Sclerosis (ALS) | Phase 2 / Phase 3 | 2013-04-01 |
| Completed | Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib Gastrointestinal Stromal Tumors | Phase 3 | 2012-04-01 |
| Completed | Masitinib in Patients With Mild to Moderate Alzheimer's Disease Alzheimer Disease | Phase 3 | 2012-01-01 |
| Completed | Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapse Free | Phase 3 | 2011-08-01 |
| Terminated | Masitinib in Refractory Active Rheumatoid Arthritis Rheumatoid Arthritis (RA) | Phase 2 / Phase 3 | 2011-07-01 |
| Terminated | A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple M Multiple Myeloma | Phase 3 | 2011-05-01 |
| Completed | Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids Asthma | Phase 3 | 2011-01-01 |
| Terminated | Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain Metastatic Melanoma | Phase 3 | 2011-01-01 |
| Terminated | Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST) Gastrointestinal Stromal Tumors | Phase 3 | 2009-01-01 |
| Completed | Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Indolent Systemic Mastocytosis | Phase 3 | 2008-12-01 |
| Completed | Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer Pancreatic Cancer | Phase 3 | 2008-11-25 |
| Completed | Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib Gastro Intestinal Stromal Tumor | Phase 2 | 2008-10-01 |
| Completed | Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis Rheumatoid Arthritis | Phase 2 | 2007-03-01 |
| Completed | Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation Mastocytosis | Phase 2 | 2007-02-01 |
| Completed | Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease Alzheimer's Disease | Phase 2 | 2006-02-01 |
| Completed | Efficacy of Oral AB1010 in Adult Patients With Severe Persistent Corticosteroid Dependent Asthma Asthma | Phase 2 | 2006-01-01 |
| Completed | A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 i Psoriasis | Phase 2 | 2005-09-01 |
| Completed | Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis Multiple Sclerosis | Phase 2 | 2005-06-01 |
| Completed | Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST) Gastro-intestinal Stromal Tumours | Phase 2 | 2005-06-01 |
| Completed | Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3 Multiple Myeloma | Phase 2 | 2005-02-01 |
| Completed | Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis Mastocytosis | Phase 2 | 2004-10-01 |
| Completed | Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis Rheumatoid Arthritis | Phase 2 | 2004-09-01 |